Psychedelic Virtual Reality
- Conditions
- Psychedelic ExperiencesVirtual RealityHealthy Volunteer
- Interventions
- Device: Meta Quest 3
- Registration Number
- NCT06581263
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this study is to evaluate a novel VRP.
- Detailed Description
The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 15
- Ability to provide informed consent
- No history or current DSM-V diagnosis
- Unstable medical conditions
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Healthy Volunteer Meta Quest 3 -
- Primary Outcome Measures
Name Time Method Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics. Day 0 through Day 30 Subject experience will be assessed using the Ego-Dissolution Inventory.
- Secondary Outcome Measures
Name Time Method Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain. Day 0 through Day 30 The number of adverse events will be assessed through qualitative interviews following VRP viewing.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States